Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of HLX10 plus chemotherapy versus placebo plus chemotherapy as neoadjuvant/adjuvant treatment for triple-negative breast cancer
CTR20192226Phase 3Suspended
- Sponsor
- HyBioPharma
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of serplulimab in triple-negative breast cancer (TNBC), sponsored by HyBioPharma. Started Dec 2019; status: suspended.
02
Drugs
serplulimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20192226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192226.